Πλήρεις δημοσιεύσεις

Πλήρεις δημοσιεύσεις


Predictors of Response to Vedolizumab in Patients with Ulcerative Colitis: Results from the Greek VEDO‑IBD Cohort
G. Bamias, G. Kokkotis, M. Gizis, C. Kapizioni, K. Karmiris, E. Koureta, N. Kyriakos, G. Leonidakis, K. Makris, P. Markopoulos, G. Michalopoulos, S. Michopoulos, I. Papaconstantinou, D. Polymeros, S. Siakavellas, K. Triantafyllou, E. Tsironi, E. Tsoukali, M. Tzouvala, N. Viazis, V. Xourafas, E. Zacharopoulou, E. Zampeli, K. Zografos, G. Papatheodoridis, G. Mantzaris
Dig Dis Sci (2021). https://doi.org/10.1007/s10620-021-06907-5

Efficacy of infliximab after failure of subcutaneous anti-TNF agents in patients with moderate to severe ulcerative colitis.
N. Viazis, Ch. Pontas, G. Karampekos, E. Tsoukali, O. Giouleme, G. Theocharis, M. Tzovala, E. Archavlis, A. Christidou, G. J. Mantzaris.
Hospital Chronicles (Nosokomeiaka Chronika). Vol. 15 No. 1 2020. 

Is there any role of renin-angiotensin system inhibitors in modulating inflammatory bowel disease outcome?
A. Mantaka, E. Tsoukali, M. Fragkaki, K. Karmiris, N. Viazis, G.J. Mantzaris, I. Koutroubakis.
Eur J Gastroenterol Hepatol. 2020 Sep 9. doi: 10.1097/MEG.0000000000001912. 

The role of coexisting cardiovascular disease on disease severity in patients with inflammatory bowel disease.
A. Mantaka, E. Tsoukali, M. Fragkaki, N. Viazis, K. Karmiris, G.J. Mantzaris, I. Koutroubakis.
Eur J Gastroenterol Hepatol. 2020 May;32(5):581-587. doi: 10.1097/MEG.0000000000001674.

Eosinophilic Esophagitis in Adults: A Concise Overview of an Evolving Disease
Mari A, Tsoukali E, Yaccob A.
Korean J Fam Med. 2020 Mar;41(2):75-83. doi: 10.4082/kjfm.18.0162. Epub 2020 Feb 17.

Screening and surveillance methods for dysplasia in inflammatory bowel disease patients: Where do we stand?
M. Galanopoulos, E. Tsoukali, F. Gkeros, M. Vraka, G. Karampekos, and G. Mantzaris.
World J Gastrointest Endosc. 2018 Oct 16; 10(10): 250–258.

Effectiveness and safety of Vedolizumab in anti-TNF-naïve patients with inflammatory bowel disease-A multicenter retrospective European study.
Kopylov U, Verstockt B, Biedermann L, Sebastian S, Pugliese D, Sonnenberg E, Steinhagen P, Arebi N, Ron Y, Kucharzik T, Roblin X, Ungar B, Shitrit AB, Ardizzone S, Molander P, Coletta M, Peyrin-Biroulet L, Bossuyt P, Avni-Biron I, Tsoukali E, Allocca M, Katsanos K, Raine T, Sipponen T, Fiorino G, Ben-Horin S, Eliakim R, Armuzzi A, Siegmund B, Baumgart DC, Kamperidis N, Maharshak N, Maaser C, Mantzaris G, Yanai H, Christodoulou DK, Dotan I, Ferrante M.
Inflamm Bowel Dis. 2018 May 18. doi: 10.1093/ibd/izy155.

Proton pump inhibitor and selective serotonin reuptake inhibitor therapy for the management of noncardiac chest pain.
Viazis N, Katopodi K, Karamanolis G, Denaxas K, Varytimiadis L, Galanopoulos M, Tsoukali E, Kamberoglou D, Christidou A, Karamanolis DG, Papatheodoridis G, Mantzaris GJ.
Eur J Gastroenterol Hepatol. 2017 Jun 16.

Investigation of extraesophageal gastroesophageal reflux disease.
E Tsoukali, D Sifrim.
Ann Gastroenterol. 2013;26(4):290-295.

Specific esophagogram to assess functional outcomes after Heller's myotomy and Dor's fundoplication for esophageal achalasia.
Tsoukali E, Gouvas N, Tsiaoussis J, Pechlivanides G, Zervakis N, Mantides A, Xynos E.
Dis Esophagus. 2011 Sep;24(7):451-7.

The role of weakly acidic reflux in proton pump inhibitor failure, has dust settled?
Tsoukali E, Sifrim D.
J Neurogastroenterol Motil. 2010 Jul;16(3):258-64.